The best supporting evidence for baseline biomarker assessment for risk assessment or prognostication comes from studies in patients with relapsed myeloma, those receiving anthracycline or anti-human epidermal growth factor receptor 2 (HER2) therapy, and those with amyloidosis. The gene discussed is ERBB2; the disease is plasma cell myeloma.